Disease · MONDO_0013860
idiopathic membranous glomerulonephritis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. idiopathic membranous glomerulonephritis. Diseases, record MONDO_0013860. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0013860
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 2 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 2 | Drugs and targets |
| BELIMUMAB | CHEMBL1789843 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IPTACOPAN | CHEMBL4594448 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RESOMELAGON ACETATE | CHEMBL5314945 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SIROLIMUS | CHEMBL413 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TACROLIMUS | CHEMBL3989887 | Small molecule | Unknown | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets7
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 2 | FK506-binding protein 1A inhibitor | Phase 2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 2 | B-lymphocyte antigen CD20 binding agent | Phase 3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 1 | Type-1 angiotensin II receptor antagonist | Unknown | https://conductscience.org/library/genes/185 | Drugs and targets |
| CFB | Complement factor B | 1 | Complement factor B inhibitor | Phase 2 | https://conductscience.org/library/genes/629 | Drugs and targets |
| PPIA | Peptidyl-prolyl cis-trans isomerase A | 1 | Cyclophilin A modulator | Unknown | https://conductscience.org/library/genes/5478 | Drugs and targets |
| TNFSF13B | Tumor necrosis factor ligand superfamily member 13B | 1 | Tumor necrosis factor ligand superfamily member 13B inhibitor | Phase 2 | https://conductscience.org/library/genes/10673 | Drugs and targets |
Trials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04154787 | Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy | Phase 2 | 37 | 2024-07-05 | Idiopathic Membranous Nephropathy | IPTACOPAN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03864250 | Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy | Not applicable | 124 | Tacrolimus, Idiopathic Membranous Nephropathy, Clinical Trial | TACROLIMUS | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03549663 | Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN) | Not applicable | 108 | Idiopathic Membranous Nephropathy | TACROLIMUS | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05914155 | Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome | Phase 3 | 88 | Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic | RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03018535 | Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy | Phase 3 | 76 | Glomerulonephritis, Membranous | CYCLOPHOSPHAMIDE, METHYLPREDNISOLONE, RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01845688 | Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy | Not applicable | 72 | Idiopathic Membranous Nephropathy | LOSARTAN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05667883 | Prognostic Model of GC/CTX in the Treatment of MN | 50 | Idiopathic Membranous Nephropathy | CYCLOPHOSPHAMIDE | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT05667896 | Prognostic Model of GC/TAC in the Treatment of MN | 50 | Idiopathic Membranous Nephropathy | TACROLIMUS | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT05667909 | Prognostic Model of Rituximab in the Treatment of MN | 50 | Idiopathic Membranous Nephropathy | RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT05667922 | Prognostic Model of TAC in the Treatment of MN | 50 | Idiopathic Membranous Nephropathy | TACROLIMUS | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0013860
GET https://conductscience.org/api/diseases/v1/MONDO_0013860/drugs